BEND3: A Protein Targeted in Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: BEND3

NCBI ID: G57673

BEND3

BEND3: A Protein Targeted in Cancer, Neurodegenerative Diseases and Autoimmune Disorders

BEND3 (BEND3_HUMAN), a protein that is expressed in various tissues of the human body, has been identified as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and various functions make it an attractive target for researchers to investigate.

The protein BEND3 is a member of the BENZOQUEIN (BQ) family, which is known for its role in various cellular processes, including cell signaling, DNA replication, and apoptosis. BEND3 is a 21-kDa protein that consists of 115 amino acid residues. It has a unique feature, a N-terminal transmembrane domain and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain is responsible for the protein's ability to interact with various cell signaling pathways, while the C-terminal cytoplasmic domain is involved in the protein's stability and functions.

One of the most significant functions of BEND3 is its role in cell signaling. BEND3 has been shown to play a role in various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. In addition, BEND3 has been shown to regulate the production of reactive oxygen species (ROS), which can cause damage to cells and contribute to various diseases, including cancer.

Another function of BEND3 is its role in neurodegenerative diseases. BEND3 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that BEND3 is expressed in the brains of individuals with these conditions and that it is involved in the production of neurodegeneration. Additionally, BEND3 has been shown to be a potential therapeutic target for neurodegenerative diseases by inhibiting its activity and increasing its levels in the brain.

In addition to its role in neurodegenerative diseases, BEND3 has also been shown to be involved in autoimmune disorders. BEND3 has been shown to play a role in the development and regulation of autoimmune diseases, including rheumatoid arthritis and multiple sclerosis. Studies have shown that BEND3 is expressed in the tissues of individuals with these conditions and that it is involved in the production of autoimmune disease. Additionally, BEND3 has been shown to be a potential therapeutic target for autoimmune disorders by inhibiting its activity and increasing its levels in the body.

In conclusion, BEND3 is a protein that has various functions in various tissues of the human body. Its unique structure and its involvement in cell signaling, neurodegenerative diseases, and autoimmune disorders make it an attractive target for researchers to investigate. Further studies are needed to fully understand the role of BEND3 in these conditions and to determine its potential as a drug target or biomarker.

Protein Name: BEN Domain Containing 3

Functions: Transcriptional repressor which associates with the NoRC (nucleolar remodeling complex) complex and plays a key role in repressing rDNA transcription. The sumoylated form modulates the stability of the NoRC complex component BAZ2A/TIP5 by controlling its USP21-mediated deubiquitination (PubMed:21914818, PubMed:26100909). Binds to unmethylated major satellite DNA and is involved in the recruitment of the Polycomb repressive complex 2 (PRC2) to major satellites (By similarity). Stimulates the ERCC6L translocase and ATPase activities (PubMed:28977671)

The "BEND3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BEND3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets